MORGAN STANLEY ASIA PRODUCTS/CALL/SINO BIOPHARMA/4.08/1/30.07.24 | Market Closed - Hong Kong S.E. 04:00:00 2024-05-24 am EDT | ||
| 0.026 HKD | -7.14% |
|
| Current month | +8.33% | ||
| 1 month | +8.33% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about SINO BIOPHARMACEUTICAL LIMITED
More news
| Date | Price | Change |
|---|---|---|
| 24-05-24 | 0.026 | -7.14% |
| 24-05-23 | 0.028 | -9.68% |
| 24-05-22 | 0.031 | -6.06% |
| 24-05-21 | 0.033 | -42.11% |
| 24-05-20 | 0.057 | +9.62% |
Delayed Quote Hong Kong S.E.
Last update May 24, 2024 at 04:00 am EDT
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | SINO BIOPHARMACEUTICAL LIMITED |
| Issuer | Morgan Stanley |
| 20885 | |
| ISIN | CH0396406149 |
| Date issued | 2023-10-30 |
| Strike | 4.08 $ |
| Maturity | 2024-07-30 (66 Days) |
| Parity | 1 : 1 |
| Emission price | 0.25 $ |
| Emission volume | N/A |
| Settlement | cash |
| Currency | HKD |
Technical Indicators
| Highest since issue | 0.56 $ |
|---|---|
| Lowest since issue | 0.014 $ |
| Spread | 0.004 $ |
| Spread % | 14.81% |
Company Profile
Sino Biopharmaceutical Limited specialises in the development, manufacture and marketing of biopharmaceutical products primarily for the treatment of cancer, ophthalmia, hepatitis, orthopedic diseases and respiratory disorders. Net sales break down by category of products as follows:
- chemical medicine products and biopharmaceutical drugs (97.6%);
- other (2.4%).
Sector
-
Ratings for Sino Biopharmaceutical Limited
Trading Rating
Investor Rating
ESG Refinitiv
B-
Consensus: Sino Biopharmaceutical Limited
Sell
Buy
Mean consensus
BUY
Number of Analysts
26
Last Close Price
2.66
CNY
Average target price
4.256
CNY
Spread / Average Target
+59.96%
- Stock Market
- Warrants
- 20885 Warrant
